News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Roche (RHHBY) Buys Rights To ORYZON Genomics's Cancer-Suppressing Gene Drug In $521 Million+ Deal



4/7/2014 6:10:04 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

(Reuters) - Roche has bought the rights to an experimental drug from Spain's Oryzon Genomics that can switch on genes to block cancer growth, as the Swiss drugmaker looks to maintain its dominance in the lucrative field of oncology.

The world's largest maker of cancer drugs will pay Barcelona-based Oryzon $21 million in upfront and near-term milestone payments and could pay out more than $500 million if the company meets other goals, it said in a statement on Monday.

Help employers find you! Check out all the jobs and post your resume.

Read at Reuters
Read at Bloomberg


comments powered by Disqus
Reuters
Bloomberg
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES